Tiziana gains as multiple sclerosis candidate improves second patient

Jun. 08, 2022 9:09 AM ETTiziana Life Sciences Ltd (TLSA)By: Dulan Lokuwithana, SA News Editor1 Comment

Diagnosis multiple sclerosis and pills.

designer491/iStock via Getty Images

  • Tiziana Life Sciences (NASDAQ:TLSA) added ~14% in the pre-market Wednesday after the clinical-stage biotech announced clinical improvements in the second patient treated with its multiple sclerosis candidate Foralumab.
  • The company noted that the results were similar to those of the first patient with secondary progressive multiple sclerosis (SPMS) after 3-months of intranasal Foralumab.
  • According to multiple measures such as clinical and PET imaging analyses, the second SPMS patient also showed an improvement following a three-month course of the fully human anti-CD3 monoclonal antibody at a 50 mcg dose.
  • The company has submitted the data to the FDA. The regulator has permitted it to enroll eight more SPMS patients to receive the initial dosing level with a provision for dose escalation up to 100 mcg.
  • Read more on the results for the first SPMS patient to receive Foralumab.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.